Lurbinectedin
Phase 1/2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Refractory Ewing Sarcoma
Conditions
Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
Trial Timeline
May 23, 2023 → Apr 20, 2028
NCT ID
NCT05734066About Lurbinectedin
Lurbinectedin is a phase 1/2 stage product being developed by Jazz Pharmaceuticals for Refractory Ewing Sarcoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05734066. Target conditions include Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma.
What happened to similar drugs?
3 of 20 similar drugs in Refractory Ewing Sarcoma were approved
Approved (3) Terminated (1) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
9
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04291937 | Pre-clinical | Completed |
| NCT06217536 | Phase 1/2 | Withdrawn |
| NCT05918640 | Phase 1/2 | Recruiting |
| NCT05734066 | Phase 1/2 | Recruiting |
| NCT05244239 | Phase 1 | Recruiting |
| NCT05126433 | Phase 2 | Terminated |
Competing Products
20 competing products in Refractory Ewing Sarcoma